Market Overview

Zalicus Prednisporin Licensee Sanofi Provides Update on Development Status

Zalicus (NASDAQ: ZLCS) today
announced that Sanofi (NYSE: SNY) provided an update on the development status of
Prednisporin™ (FOV1101) during the course of Sanofi's quarterly
financial and R&D pipeline update on October 25, 2012. Prednisporin is a
fixed dose combination of prednisolone acetate and cyclosporine A being
developed for certain ophthalmologic indications including persistent
allergic conjunctivitis. Prednisporin was licensed by Zalicus to Fovea
Pharmaceuticals SA (now a division of Sanofi) in January 2006.

Based on a recent review of prior Phase 2b results for Prednisporin,
Sanofi has reassessed the commercial profile for Prednisporin and has
made

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters